Brain-Iron-as-a-Service: Ventio accelerates its ambition to revolutionize the diagnosis of neurodegenerative diseases

Brain-Iron-as-a-Service: Ventio accelerates its ambition to revolutionize the diagnosis of neurodegenerative diseases

Our mission: to better understand, diagnose earlier, and accurately monitor neurodegenerative diseases by tracking brain iron.

To achieve this mission, we have taken three major steps:

✅ A partnership to strengthen understanding of these diseases
Launch of the QSM for Alzheimer’s Disease project, in partnership with the CEA and the Paris Psychiatry & Neurosciences University Hospital Group (GHU) – Sainte-Anne. Together, we will explore the role of intracerebral iron in Alzheimer’s disease to precisely identify the regions affected.

✅ Opening of a branch in Paris
Our Paris office supports the growth of our activities, brings us closer to our partners, and places us at the heart of the medical and scientific network in the Île-de-France region.

✅ Acceleration of market launch
A capital increase allows us to aim for CE marking, strengthen our partnerships, and support our deployment in all territories.

Our Brain-Iron-as-a-Service approach is part of a dynamic of disruptive innovation, supported by the France 2030 Investment Program for the Future. This strategic support validates our vision: to transform patient care through our high-impact societal solutions based on brain iron.